IGF-1 vs IGF-1 LR3 for recovery
Short answer: For recovery, more users report improvement with IGF-1 — 100% of 3 reports, versus 93% of 15 for IGF-1 LR3.
IGF-1 has 276 meta-analyses and 736 randomized trials on PubMed; IGF-1 LR3 has 0 and 0.
Based on 22 reports about IGF-1 and 78 about IGF-1 LR3. Not medical advice.
| IGF-1 Peptide | IGF-1 LR3 Peptide | |
|---|---|---|
| Users say it helped | 70%helped7 reports · few reports | 60%helped35 reports · medium confidence |
| Verdict | Mostly positive | Mostly positive |
| Research | AResearch: Strong | DResearch: None |
| Meta-analyses / RCTs | 276 / 736 | 0 / 0 |
| Mainly used for | ||
| Performance % reporting improvement | — | 91% (22) |
| Recovery % reporting improvement | 100% (3) | 93% (15) |
| Weight loss % reporting improvement | — | 100% (6) |
| Pain & inflammation % reporting improvement | — | 83% (6) |
| Common side effects | cancer risk, extreme itching | hypoglycemia, permagut, drowsiness, tumor growth |
| Typical dose reported | Not listed | Not listed |
IGF-1Full IGF-1 profile →
Latest review conclusion
To date, there are no convincing data that weight loss could improve the prognosis of treated neoplasia. However, a regular physical activity and a limited caloric intake are probably safe in healthy subject to prevent cancer and also in cancer survivors.
Rev Med Interne, 2009 ↗What a user said
“I've gotten legit igf once or twice and simply put it was the most amazing compound I've ever used amazing pumps”
IGF-1 LR3Full IGF-1 LR3 profile →
What a user said
“I've tried growth hormone and IGF-1 LR3 and I feel like they increased the effectiveness by 1.5-2x depending on the dosage used.”
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate